Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

Pensel, Patricia Eugenia; Gamboa, Gabriela Verónica Ullio; Fabbri, Julia; Ceballos, Laura; Bruni, Sergio Fabian Sanchez; Álvarez, Luis Ignacio Ortega; Allemandi, Daniel Alberto; Benoit, Jean‐Pierre; Palma, Santiago Daniel; Elissondo, Marı́a Celina

doi:10.1016/j.actatropica.2015.09.016

Cited by 53 publications

(25 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(26). However, in recent years, many authors reported that an encapsulated lipid formulation of albendazole may achieve higher intracystic and intraplasmic concentrations that will increase treatment response rates (30). In our study, only medical therapy was successful in 21 (8%) patients.…”

Section: Discussionmentioning

confidence: 55%

“…Spleen (12) 77.7 (7) Splenectomy (6) Cystostomy and drainage (1) Bone (5) 100 (5) Debridement (3) Partial cystectomy and drainage (1) Mesentery (7) 85.1 (6) Small bowel resection (1) Cystectomy (5) Omentum (6) 100 (6) Cystectomy (6) Muscle (3) 100 (3) Cystectomy (3) Brain (2) 100 (2) Cystectomy (2) Adrenal (1) 100 (1) Cystectomy (1) Bladder (1) 100 (1) Cystectomy (1) Pancreas (1) 100 (1) Cystectomy (1) Turkiye Parazitol Derg 2017; 41: [28][29][30][31][32][33] Türkoğlu at al. Cystic Echinococcosis and lack of disease control programs (1,6,7).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Evaluation of Patients with Cystic Echinococcosis

Türkoğlu¹,

Demirtürk²,

Tünay³

et al. 2017

TurkiyeParazitolDerg

View full text Add to dashboard Cite

Objective: Cystic echinococcosis (CE) is a globally prevalent zoonotic disease. Methods: Demographic, clinical, laboratory, and follow-up data of patients between May 2009 and 2015 were retrospectively analyzed by screening data from a hospital automation system. Results: A total of 238 (females, n=139 and males, n=99) patients with a mean age of 40.6±20.58 years were included. Less than half (40.8%) of the patients were living in the countryside. Hepatic involvement of CE was most frequently (72.2%) seen. A majority (75.6%) of the patients were symptomatic, but abdominal pain was the most frequently seen symptom. For diagnosis, in all patients, imaging modalities were used, while in 66% of the patients, serological methods were also employed. The patients received both medical and surgical treatments (78.5%, n=187), only surgical treatment (10.5%, n=25), or only medical treatment (8.8%, n=21). Surgical treatment was performed for patients with hepatic (n=139/176, 80.6%), pulmonary (n=78/94, 82.9%), splenic (n=7/9; 77.7%), and mesenteric (n=6/7, 85.1%) cysts, and patients cases with brain, bone, muscle, omentum, bladder, and adrenal cysts had undergone surgical intervention. Conclusion: Publication of regional data is important in terms of epidemiological considerations and may aid in the formulation of standard treatment approaches. En sık tutulan organ karaciğer (%72,2) idi. Hastaların %75,6'sı semptomatik olup en sık görülen semptom karın ağrısı idi. Tanıda tüm hastalarda görüntüleme yöntemine başvurulurken, %66' sında serolojik yöntem de kullanılmıştı. Hastaların % 78,5'i (n=187) hem medikal hem cerrahi tedavi, %10,5'i (n=25) yalnız cerrahi tedavi, %8,8'i (n=21) ise yalnız medikal tedavi almıştı. Karaciğer tutulumu saptanan 173 hastanın %80,6'sına (n=139), akciğer tutulumu saptanan 94 hastanın %82,9'una (n=78), dalakta tutulum saptanan 9 hastanın %77,7' sine (n=7), mesenterde kist saptanan 7 hastanın %85,1'ine (n=6); beyin, kemik, kas, omentum, mesane ve sürrenalde kist saptananların ise tümüne cerrahi uygulandığı tespit edildi. Sonuç: Bölgesel verilerin yayınlanması, epidemiyolojik açıdan önem taşıdığı gibi standart tedavi algoritmalarının oluşturulmasına yardımcı olabilir.

show abstract

Section: Discussionmentioning

confidence: 55%

Section: Discussionmentioning

confidence: 99%

Evaluation of Patients with Cystic Echinococcosis

Türkoğlu¹,

Demirtürk²,

Tünay³

et al. 2017

TurkiyeParazitolDerg

View full text Add to dashboard Cite

show abstract

“…30 Inclusion of both additives resulted in slight changes in colloidal properties of PZQ-LNCs (Table 1), indicating uniform PZQ distribution within the LNC core, the reduction in size being attributed to enhanced emulsification during LNCs' formation. 30 Similar to other lipophilic drugs such as paclitaxel and albendazole, 28,47 PZQ was efficiently entrapped in the LNCs oily core (EE .95%) allowing a payload of 86.3 mg/g for PZQ-OA-MFS-LNC-25 (Table 1).…”

Section: Discussionmentioning

confidence: 99%

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting

Amara¹,

Ramadan²,

El‐Moslemany³

et al. 2018

IJN

View full text Add to dashboard Cite

PurposeLipid nanocapsules (LNCs) have shown potential to increase the bioavailability and efficacy of orally administered drugs. However, their intestinal translocation to distal target sites and their implication in pharmacokinetic (PK)–pharmacodynamic (PD) relationships are yet to be elucidated. In this study, the effect of LNCs on the PD activity and pharmacokinetics of praziquantel (PZQ), the mainstay of schistosomiasis chemotherapy, was investigated.Materials and methodsThe composition of LNCs was modified to increase PZQ payload and to enhance membrane permeability. PZQ–LNCs were characterized in vitro for colloidal properties, entrapment efficiency (EE%), and drug release. PD activity of the test formulations was assessed in Schistosoma mansoni-infected mice 7 days post-oral administration of a single 250 mg/kg oral dose. Pharmacokinetics of the test formulations and their stability in simulated gastrointestinal (GI) fluids were investigated to substantiate in vivo data.ResultsPZQ–LNCs exhibited good pharmaceutical attributes in terms of size (46–62 nm), polydispersity index (0.01–0.08), EE% (>95%), and sustained release profiles. Results indicated significant efficacy enhancement by reduction in worm burden, amelioration of liver pathology, and extensive damage to the fluke suckers and tegument. This was partly explained by PK data determined in rats. In addition, oral targeting of the worms was supported by the stability of PZQ–LNCs in simulated GI fluids and scanning electron microscopy (SEM) visualization of nanostructures on the tegument of worms recovered from mesenteric/hepatic veins. Cytotoxicity data indicated tolerability of PZQ–LNCs.ConclusionData obtained provide evidence for the ability of oral LNCs to target distal post-absorption sites, leading to enhanced drug efficacy. From a practical standpoint, PZQ–LNCs could be suggested as a potential tolerable single lower dose oral nanomedicine for more effective PZQ mass chemotherapy.

show abstract

“…Despite high permeability of ABZ, based on its biopharmaceutical classification system (BCS) type II status (Jung, Medina, Garcia, Fuentes, & Moreno-Esparza, 1998), its low aqueous solubility (0.2 μg/mL in water at 25C) and low oral absorption (≤5%) could limit the potential use of ABZ in cancer treatment (García et al, 2014;Pensel et al, 2015).…”

Section: Introductionmentioning

confidence: 99%

Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles

Kang

Choi

Lee

et al. 2017

Carbohydrate Polymers

View full text Add to dashboard Cite

Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

Cited by 53 publications

References 39 publications

Evaluation of Patients with Cystic Echinococcosis

Evaluation of Patients with Cystic Echinococcosis

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting

Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles

Contact Info

Product

Resources

About

Cystic echinococcosis therapy: Albendazole-loaded lipid nanocapsules enhance the oral bioavailability and efficacy in experimentally infected mice

Cited by 53 publications

References 39 publications

Evaluation of Patients with Cystic Echinococcosis

Evaluation of Patients with Cystic Echinococcosis

Praziquantel&ndash;lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting

Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan-coated PLGA nanoparticles

Contact Info

Product

Resources

About

Praziquantel–lipid nanocapsules: an oral nanotherapeutic with potential <em>Schistosoma mansoni</em> tegumental targeting